New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
07:01 EDTDNDNDendreon: Immune responses enhanced when Provenge given after ADT
Dendreon Corporation announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology Congress taking place from April 11-15, 2014 in Stockholm, Sweden.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
16:15 EDTDNDNDendreon names W. Thomas Amick as president, CEO
Dendreon announced that its board has appointed W. Thomas Amick as president and CEO, effective immediately. Amick has also been appointed to the company’s board of directors. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and CEO for personal reasons. Johnson will work with Amick through August 15 to ensure a smooth transition. Most recently from 2010 to 2012, Amick served as chairman and CEO of Discovery Labs, a specialty biotechnology company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use